Cytokinetics (NASDAQ:CYTK) Lowered to Sell at BidaskClub

BidaskClub downgraded shares of Cytokinetics (NASDAQ:CYTK) from a hold rating to a sell rating in a research report sent to investors on Saturday, BidAskClub reports.

Several other analysts also recently issued reports on the company. Zacks Investment Research upgraded Cytokinetics from a sell rating to a hold rating in a report on Monday, November 4th. Cantor Fitzgerald reiterated an overweight rating and issued a $20.00 price target (up from $14.00) on shares of Cytokinetics in a report on Friday, September 6th. HC Wainwright reiterated a buy rating and issued a $26.00 price target on shares of Cytokinetics in a report on Friday, October 4th. Morgan Stanley set a $16.00 price target on Cytokinetics and gave the company a hold rating in a report on Friday, August 9th. Finally, JMP Securities set a $23.00 price target on Cytokinetics and gave the company a buy rating in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. Cytokinetics presently has a consensus rating of Hold and a consensus target price of $19.86.

CYTK stock traded down $0.07 on Friday, reaching $8.20. The company had a trading volume of 5,309,400 shares, compared to its average volume of 528,164. Cytokinetics has a 1 year low of $5.75 and a 1 year high of $14.94. The company has a market cap of $654.04 million, a P/E ratio of -4.21 and a beta of 1.54. The company has a debt-to-equity ratio of 12.35, a quick ratio of 8.42 and a current ratio of 8.20. The company’s fifty day moving average is $11.43 and its 200 day moving average is $11.39.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.06. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 378.70%. The firm had revenue of $6.06 million during the quarter, compared to the consensus estimate of $7.80 million. On average, sell-side analysts predict that Cytokinetics will post -2.02 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other Cytokinetics news, CEO Robert I. Blum sold 6,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.74, for a total value of $76,440.00. Following the completion of the transaction, the chief executive officer now directly owns 244,022 shares of the company’s stock, valued at approximately $3,108,840.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 22,500 shares of company stock valued at $271,575. 5.70% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the business. Aperio Group LLC purchased a new position in Cytokinetics in the 2nd quarter valued at about $183,000. Parametric Portfolio Associates LLC boosted its position in Cytokinetics by 32.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 104,570 shares of the biopharmaceutical company’s stock valued at $1,176,000 after buying an additional 25,783 shares during the last quarter. Vanguard Group Inc. boosted its position in Cytokinetics by 3.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,961,497 shares of the biopharmaceutical company’s stock valued at $44,566,000 after buying an additional 147,849 shares during the last quarter. Swiss National Bank boosted its position in Cytokinetics by 5.5% in the 2nd quarter. Swiss National Bank now owns 86,600 shares of the biopharmaceutical company’s stock valued at $974,000 after buying an additional 4,500 shares during the last quarter. Finally, Morgan Stanley boosted its position in Cytokinetics by 220.0% in the 2nd quarter. Morgan Stanley now owns 286,236 shares of the biopharmaceutical company’s stock valued at $3,220,000 after buying an additional 196,786 shares during the last quarter. 76.13% of the stock is owned by institutional investors.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Recommended Story: Cryptocurrencies

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Leave a Reply

Your email address will not be published. Required fields are marked *

*